ARS Pharmaceuticals, Inc. (SPRY)
5.96
-0.04
(-0.67%)
USD |
NASDAQ |
Sep 01, 10:10
ARS Pharmaceuticals Cash from Operations (TTM) : -196.40M for June 30, 2026
Cash from Operations (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -196.40M |
| March 31, 2026 | -175.07M |
| December 31, 2025 | -170.87M |
| September 30, 2025 | -85.38M |
| June 30, 2025 | -52.80M |
| March 31, 2025 | -20.48M |
| December 31, 2024 | 13.55M |
| September 30, 2024 | -45.86M |
| June 30, 2024 | -44.16M |
| March 31, 2024 | -53.55M |
| December 31, 2023 | -59.27M |
| September 30, 2023 | -30.46M |
| Date | Value |
|---|---|
| June 30, 2023 | -23.38M |
| March 31, 2023 | -13.69M |
| December 31, 2022 | -8.184M |
| September 30, 2022 | 8.313M |
| June 30, 2022 | -5.124M |
| March 31, 2022 | -12.28M |
| December 31, 2021 | -17.56M |
| September 30, 2021 | -56.55M |
| June 30, 2021 | -44.46M |
| March 31, 2021 | -35.77M |
| December 31, 2020 | -31.20M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Passage Bio, Inc. | -33.50M |
| Vertex Pharmaceuticals, Inc. | 4.293B |
| Capricor Therapeutics, Inc. | -104.00M |
| Kyntra Bio, Inc. | -38.05M |
| Zentalis Pharmaceuticals, Inc. | -128.10M |